Top

Published in:

01-05-2009 | Original Article

Azithromycin Reduces Gastroesophageal Reflux and Aspiration in Lung Transplant Recipients

Authors: V. Mertens, K. Blondeau, A. Pauwels, R. Farre, B. Vanaudenaerde, R. Vos, G. Verleden, D. E. Van Raemdonck, L. J. Dupont, D. Sifrim

Published in: Digestive Diseases and Sciences | Issue 5/2009

Abstract

Azithromycin (AZI) is a macrolide antibiotic that improves lung function in lung transplant recipients (LTx). Gastroesophageal reflux (GER) has been implicated in the pathogenesis of chronic rejection after LTx. Macrolide antibiotics may affect GER by modifying esophageal and gastric motility. The purpose of this study was to evaluate the effect of AZI on GER and gastric aspiration after LTx. Acid and weakly acidic GER was measured with 24-h pH-impedance monitoring in 47 LTx patients (12 patients “on” AZI). Gastric aspiration was assessed in a separate group of 30 LTx patients before and after AZI by measurements of pepsin and bile acid in bronchoalveolar lavage fluid (BALF). Patients “on” AZI had a significant lower total number of reflux events [41 (30–61) vs. 22.5 (7–37.5)], number of acid reflux events [24 (16–41) vs. 8 (4–18)], esophageal acid exposure [2.9% (0.7–7.3) vs. 0.2% (0.1–2.0)], bolus exposure [0.73% (0.5–1.4) vs. 0.21% (0.12–0.92)], and proximal extent of reflux [14 (9–24) vs. 5 (2–7)]. AZI reduced the concentration of bile acids in BALF without affecting levels of pepsin. LTx patients “on” AZI have less GER and bile acids aspiration. This effect might be due to enhanced esophageal motility and accelerated gastric emptying.

Irwin RS, Corrao WM, Pratter MR. Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy. Am Rev Respir Dis. 1981;123(4 Pt 1):413–417.PubMed

Sifrim D, Dupont L, Blondeau K, Zhang X, Tack J, Janssens J. Weakly acidic reflux in patients with chronic unexplained cough during 24-hour pressure, pH, and impedance monitoring. Gut. 2005;54(4):449–454. doi:10.1136/gut.2004.055418.PubMedCrossRef

Feigelson J, Sauvegrain J. Letter: Gastro-esophageal reflux in mucoviscidosis. Nouv Presse Med. 1975;4(38):2729–2730.PubMed

Blondeau K, Dupont L, Mertens V, Verleden G, Malfroot A, Vandenplas Y, Hauser B, Sifrim D. Gastroesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis. Gut. 2008;57:1049–1055.

Rosztoczy A, Makk L, Izbeki F, Roka R, Somfay A, Wittmann T. Asthma and gastroesophageal reflux: clinical evaluation of esophago-bronchial reflex and proximal reflux. Digestion. 2008;77(3–4):218–224. doi:10.1159/000146083.PubMedCrossRef

Harding SM. The potential role of gastroesophageal reflux in asthma. Minerva Gastroenterol Dietol. 2001;47(2):75–83.PubMed

Blondeau K, Mertens V, Vanaudenaerde BA, et al. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J. 2008;31(4):707–713. doi:10.1183/09031936.00064807.PubMedCrossRef

D’Ovidio F, Keshavjee S. Gastroesophageal reflux and lung transplantation. Dis Esophagus. 2006;19(5):315–320. doi:10.1111/j.1442-2050.2006.00603.x.PubMedCrossRef

Palmer SM, Miralles AP, Howell DN, Brazer SR, Tapson VF, Davis RD. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest. 2000;118(4):1214–1217. doi:10.1378/chest.118.4.1214.PubMedCrossRef

10.

Young LR, Hadjiliadis D, Davis RD, Palmer SM. Lung transplantation exacerbates gastroesophageal reflux disease. Chest. 2003;124(5):1689–1693. doi:10.1378/chest.124.5.1689.PubMedCrossRef

11.

Stordal K, Johannesdottir GB, Bentsen BS, et al. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. Arch Dis Child. 2005;90(9):956–960. doi:10.1136/adc.2004.068890.PubMedCrossRef

12.

Jiang SP, Liang RY, Zeng ZY, Liu QL, Liang YK, Li JG. Effects of antireflux treatment on bronchial hyper-responsiveness and lung function in asthmatic patients with gastroesophageal reflux disease. World J Gastroenterol. 2003;9(5):1123–1125.PubMed

13.

Bocskei C, Viczian M, Bocskei R, Horvath I. The influence of gastroesophageal reflux disease and its treatment on asthmatic cough. Lung. 2005;183(1):53–62. doi:10.1007/s00408-004-2526-z.PubMedCrossRef

14.

Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole. Eur Respir J. 2000;16(4):633–638. doi:10.1034/j.1399-3003.2000.16d11.x.PubMedCrossRef

15.

Tutuian R, Mainie I, Agrawal A, Adams D, Castell DO. Nonacid reflux in patients with chronic cough on acid-suppressive therapy. Chest. 2006;130(2):386–391. doi:10.1378/chest.130.2.386.PubMedCrossRef

16.

Mainie I, Tutuian R, Agrawal A, et al. Fundoplication eliminates chronic cough due to non-acid reflux identified by impedance pH monitoring. Thorax. 2005;60(6):521–523. doi:10.1136/thx.2005.040139.PubMedCrossRef

17.

Boesch RP, Acton JD. Outcomes of fundoplication in children with cystic fibrosis. J Pediatr Surg. 2007;42(8):1341–1344. doi:10.1016/j.jpedsurg.2007.03.030.PubMedCrossRef

18.

Cantu E III, Appel JZ III, Hartwig MG, et al. J. Maxwell Chamberlain memorial paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg. 2004;78(4):1142–1151. doi:10.1016/j.athoracsur.2004.04.044.PubMedCrossRef

19.

Hartwig MG, Appel JZ, Davis RD. Antireflux surgery in the setting of lung transplantation: strategies for treating gastroesophageal reflux disease in a high-risk population. Thorac Surg Clin. 2005;15(3):417–427. doi:10.1016/j.thorsurg.2005.03.001.PubMedCrossRef

20.

O’Halloran EK, Reynolds JD, Lau CL, et al. Laparoscopic Nissen fundoplication for treating reflux in lung transplant recipients. J Gastrointest Surg. 2004;8(1):132–137. doi:10.1016/j.gassur.2003.10.1013.PubMedCrossRef

21.

Mansi C, Borro P, Giacomini M, et al. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther. 2000;14(5):561–569. doi:10.1046/j.1365-2036.2000.00742.x.PubMedCrossRef

22.

Fink SM, Lange RC, McCallum RW. Effect of metoclopramide on normal and delayed gastric emptying in gastroesophageal reflux patients. Dig Dis Sci. 1983;28(12):1057–1061. doi:10.1007/BF01295802.PubMedCrossRef

23.

McCallum RW, Fink SM, Lerner E, Berkowitz DM. Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterology. 1983;84(6):1573–1577.PubMed

24.

Takeda T, Konomi H, Naritomi G, et al. Single oral dose of cisapride accelerates gastric antral emptying in healthy humans: an ultrasonographic study. J Gastroenterol. 1996;31(3):323–328. doi:10.1007/BF02355019.PubMedCrossRef

25.

Campo S, Morini S, Re MA, et al. Esophageal dysmotility and gastroesophageal reflux in intrinsic asthma. Dig Dis Sci. 1997;42(6):1184–1188. doi:10.1023/A:1018841704897.PubMedCrossRef

26.

Fouad YM, Katz PO, Hatlebakk JG, Castell DO. Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms. Am J Gastroenterol. 1999;94(6):1464–1467. doi:10.1111/j.1572-0241.1999.1127_e.x.PubMedCrossRef

27.

Malfroot A, Dab I. New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up. Arch Dis Child. 1991;66(11):1339–1345. doi:10.1136/adc.66.11.1339.PubMedCrossRef

28.

Poe RH, Kallay MC. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. Chest. 2003;123(3):679–684. doi:10.1378/chest.123.3.679.PubMedCrossRef

29.

Vandenplas Y. Clinical use of cisapride and its risk-benefit in paediatric patients. Eur J Gastroenterol Hepatol. 1998;10(10):871–881. doi:10.1097/00042737-199810000-00011.PubMedCrossRef

30.

Chen CL, Orr WC, Verlinden MH, et al. Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16(4):749–757. doi:10.1046/j.1365-2036.2002.01218.x.PubMedCrossRef

31.

Netzer P, Schmitt B, Inauen W. Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16(8):1481–1490. doi:10.1046/j.1365-2036.2002.01324.x.PubMedCrossRef

32.

Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003;168(1):121–125. doi:10.1164/rccm.200212-1424BC.PubMedCrossRef

33.

Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004;77(9):1465–1467. doi:10.1097/01.TP.0000122412.80864.43.PubMedCrossRef

34.

Yates B, Murphy DM, Forrest IA, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2005;172(6):772–775. doi:10.1164/rccm.200411-1537OC.PubMedCrossRef

35.

Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174(5):566–570. doi:10.1164/rccm.200601-071OC.PubMedCrossRef

36.

Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21(3):297–310. doi:10.1016/S1053-2498(02)00398-4.PubMedCrossRef

37.

Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53(7):1024–1031. doi:10.1136/gut.2003.033290.PubMedCrossRef

38.

Zerbib F, des Varannes SB, Roman S, et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects. Aliment Pharmacol Ther. 2005;22(10):1011–1021. doi:10.1111/j.1365-2036.2005.02677.x.PubMedCrossRef

39.

Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1829–1832.PubMed

40.

Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol. 2001;31(6):464–473. doi:10.1002/ppul.1076.PubMedCrossRef

41.

Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008;85(1):36–41.PubMedCrossRef

42.

D’Ovidio F, Mura M, Tsang M, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg. 2005;129(5):1144–1152. doi:10.1016/j.jtcvs.2004.10.035.PubMedCrossRef

43.

D’Ovidio F, Mura M, Ridsdale R, et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am J Transplant. 2006;6(8):1930–1938. doi:10.1111/j.1600-6143.2006.01357.x.PubMedCrossRef

44.

Hadjiliadis D, Duane DR, Steele MP, et al. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant. 2003;17(4):363–368. doi:10.1034/j.1399-0012.2003.00060.x.PubMedCrossRef

45.

Palmer SM. Reflux of bile acids: an innate problem of lung transplantation. Am J Transplant. 2006;6(8):1757–1758. doi:10.1111/j.1600-6143.2006.01425.x.PubMedCrossRef

46.

Davis RD Jr, Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg. 2003;125(3):533–542. doi:10.1067/mtc.2003.166.PubMedCrossRef

47.

Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology. 1993;105(6):1886–1899.PubMed

48.

Thielemans L, Depoortere I, Perret J, et al. Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005;313(3):1397–1405. doi:10.1124/jpet.104.081497.PubMedCrossRef

49.

Sifrim D, Blondeau K. Technology insight: the role of impedance testing for esophageal disorders. Nat Clin Pract Gastroenterol Hepatol. 2006;3(4):210–219. doi:10.1038/ncpgasthep0446.PubMedCrossRef

50.

Bala I, Prasad K, Bhukal I, Nakra D, Pratap M. Effect of preoperative oral erythromycin, erythromycin-ranitidine, and ranitidine-metoclopramide on gastric fluid pH and volume. J Clin Anesth. 2008;20(1):30–34. doi:10.1016/j.jclinane.2007.08.002.PubMedCrossRef

51.

Asai T, Murao K, Shingu K. Pre-operative oral erythromycin reduces residual gastric volume and acidity. Br J Anaesth. 2000;85(6):861–864. doi:10.1093/bja/85.6.861.PubMedCrossRef

52.

Memis D, Turan A, Karamanlioglu B, et al. Effect of preoperative oral use of erythromycin and nizatidine on gastric pH and volume. Anaesth Intensive Care. 2002;30(4):428–432.PubMed

53.

Clarke AT, Wirz AA, Manning JJ, Ballantyne SA, Alcorn DJ, McColl KE. Severe reflux disease is associated with an enlarged unbuffered proximal gastric acid pocket. Gut. 2008;57(3):292–297. doi:10.1136/gut.2006.109421.PubMedCrossRef

54.

Bisschops R, Sifrim D, Vos R, Janssens J, Tack J. Influence of gastric motility modifying drugs on the postprandial acid and bile pockets at the gastro-esophageal junction. Gastroenterology (in press).

55.

Sifrim D, Matsuo H, Janssens J, Vantrappen G. Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man. Drugs Exp Clin Res. 1994;20(3):121–126.PubMed

56.

Ward C, Forrest IA, Brownlee IA, et al. Pepsin like activity in bronchoalveolar lavage fluid is suggestive of gastric aspiration in lung allografts. Thorax. 2005;60(10):872–874. doi:10.1136/thx.2004.036426.PubMedCrossRef

57.

Mertens V, Blondeau K, Vanaudenaerde BM, et al. Pepsin or bile acids: what is the best marker of gastric aspiration in lung transplant recipients? J Heart Lung Transplant. 2008;27(2):S125–S126. doi:10.1016/j.healun.2007.11.188.CrossRef

58.

Koek GH, Vos R, Sifrim D, Cuomo R, Janssens J, Tack J. Mechanisms underlying duodeno-gastric reflux in man. Neurogastroenterol Motil. 2005;17(2):191–199. doi:10.1111/j.1365-2982.2004.00633.x.PubMedCrossRef

59.

Fountos A, Chrysos E, Tsiaoussis J, et al. Duodenogastric reflux after biliary surgery: scintigraphic quantification and improvement with erythromycin. ANZ J Surg. 2003;73(6):400–403. doi:10.1046/j.1445-2197.2003.t01-1-02654.x.PubMedCrossRef

Title: Azithromycin Reduces Gastroesophageal Reflux and Aspiration in Lung Transplant Recipients
Authors: V. Mertens
K. Blondeau
A. Pauwels
R. Farre
B. Vanaudenaerde
R. Vos
G. Verleden
D. E. Van Raemdonck
L. J. Dupont
D. Sifrim
Publication date: 01-05-2009
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 5/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-009-0725-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Comparative Effects of a High-Amylose Starch and a Fructooligosaccharide on Fecal Bifidobacteria Numbers and Short-Chain Fatty Acids in Pigs Fed Bifidobacterium animalis

Synbiotics Decrease the Incidence of Septic Complications in Patients with Severe SIRS: A Preliminary Report

Lansoprazole for Long-Term Maintenance Therapy of Erosive Esophagitis: Double-Blind Comparison with Ranitidine

The Simultaneous Expression of Peroxisome Proliferator-Activated Receptor Delta and Cyclooxygenase-2 May Enhance Angiogenesis and Tumor Venous Invasion in Tissues of Colorectal Cancers

Effect of Preoperative Intravenous Pantoprazole in Elective-Surgery Patients: A Pilot Study

Independent Factors Associated with Recurrent Bleeding in Cirrhotic Patients with Esophageal Variceal Hemorrhage

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage